Premium
Effects of glitazones in the treatment of diabetes and/or hyperlipidaemia: glycaemic control and plasma lipid levels
Author(s) -
Vergès Bruno
Publication year - 2007
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1111/j.1472-8206.2007.00532.x
Subject(s) - pioglitazone , rosiglitazone , medicine , endocrinology , cholesterol , diabetes mellitus , thiazolidinedione , type 2 diabetes , high density lipoprotein
Both pioglitazone and rosiglitazone are effective hypoglycaemic agents in monotherapy as in combined therapy. Interestingly, their reducing effect on fasting glycaemia and HbA1c is maintained over time, suggesting a potential protective effect of glitazones on the pancreatic beta‐cells. The effects on lipids of pioglitazone are more favourable than those of rosiglitazone. Indeed, pioglitazone appears to be well suited for diabetic dyslipidaemia, increasing high‐density lipoprotein (HDL)‐cholesterol, decreasing triglycerides and small, dense low‐density (LDL) particles with usually no effect on plasma LDL‐cholesterol. Rosiglitazone also increases HDL‐cholesterol, but has no effect on triglycerides and increases plasma LDL‐cholesterol.